AGENUS INC logo

AGENUS INC

0001098972

Agenus is a biotechnology company focused on developing and commercializing immuno-oncology therapies. Their key products include botensilimab and balstilimab, which are in clinical trials for various cancers. The company is positioned as an innovator in the development of next-generation immunotherapies.

86
Altamente Confiable
Puntuación de Confianza

Registro Oficial

Número de IVA
061562417
Dirección
3 FORBES ROAD, LEXINGTON, MA 02421
Códigos de Industria
Biological Products, (No Diagnostic Substances), 2836

Análisis de Calidad IA

Industria
Biotechnology
SSL/HTTPS
Seguro
Correo profesional
Correo de contacto
med.info@agenusbio.com

🌟 Empresas similares de confianza

Context Therapeutics Inc.

Context Therapeutics Inc. logo
86/100 · Altamente Confiable

Context Therapeutics is dedicated to advancing the treatment of solid tumors through the development of next-generation T cell engaging (TCE) bispecific antibody therapies. Their innovative pipeline features clinical-stage bispecific therapeutics designed to harness the immune system for targeted cancer eradication. The company focuses on innovative immunotherapeutic solutions, transforming cancer care and improving outcomes for patients.

2001 MARKET STREET, Estados Unidos
Ver perfil

Evaxion A/S

Evaxion A/S logo
77/100 · Confiable

Evaxion utilizes its AI-Immunology™ platform to challenge and improve standardized treatments. In oncology, they create personalized therapies, tailoring treatment to the individual. For infectious diseases, they design next-generation vaccines to address unmet medical needs. Their AI platform accelerates vaccine target discovery, design, and development.

DR NEERGAARDS VEJ 5F, Estados Unidos
Ver perfil

BRAINSTORM CELL THERAPEUTICS INC.

BRAINSTORM CELL THERAPEUTICS INC. logo
89/100 · Altamente Confiable

BrainStorm is a leader in developing innovative autologous cellular therapies for neurodegenerative diseases. They focus on creating transformative treatments using MSC-NTF cells and autologous cellular therapy. The company strives to defeat debilitating neurodegenerative conditions and improve patient outcomes.

1325 AVENUE OF AMERICAS, Estados Unidos
Ver perfil